Loading...

          

Athens Conference on Plasma Cell Dyscrasias - September 11-12, 2009
Loading...

Is complete response an important endpoint in the current management of multiple myeloma?  »    PDF - 357 kB

Raymond Alexanian, M.D.
MD Anderson Cancer Center, Houston, Texas (USA)
Moving Scientific Advances from Bench to Bedside  »    PDF - 2.882 kB

Kenneth C. Anderson, M.D.
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Harvard Medical School, USA
The Arkansas approach to the treatment of multiple myleoma: 20 years of experience  »    PDF - 6.457 kB

Bart Barlogie, M.D.
Myeloma Institute for Research and Therapy
University of Arkansas for medical Sciences
Little Rock AR, USA
Which are the relevant prognostic factors in the current management of multiple myeloma ...  »    PDF - 518 kB

Joan Bladé, M.D.
Hospital Clinic, Hematology
Villarroel 170, Barcelona, Spain
Treatment of relapsed/refractory myeloma  »    PDF - 787 kB

Meletios Athanasios Dimopoulos, M.D.
Department of Clinical Therapeutics
University of Athens School of Medicine, Greece
Cutaneous, renal and neurological manifestations of plasma cell dyscrasias  »    PDF - 2.409 kB

Prof. Jean-Paul Fermand
Immuno-Hematology Unit
Saint-Louis Hospital, Paris, France
Stem cell Transplantation in Multiple Myeloma in 2009  »    PDF - 1.271 kB

Prof. Jean-Luc Harousseau
Professor of Hematology (University of Nantes)
Director Rene Gauducheau Cancer Center, France
Management of anemia and neurological complications in multiple myeloma  »    PDF - 671 kB

Eirini Katodritou, M.D.
Hematology Department
Theagenion Cancer Center
Thessaloniki, Greece
Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma ...  »    PDF - 535 kB

Robert A. Kyle, M.D.
Mayo Clinic
Rochester, Minnesota, USA
IMF Scientific Advisory Board Chairman
Diagnosis, prognosis and management of systemic light chain amyloidosis  »    PDF - 2.991 kB

Giampaolo Merlini, M.D.
Amyloid Research and Treatment Center
Fondazione IRCCS Policlinico San Matteo
University of Pavia, Italy
gmerlini@unipv.it
New treatment strategies for multiple myeloma. The GIMEMA experience  »    PDF - 648 kB

Antonio Palumbo, M.D.
Div. Hematology, University of Torino, EU
Treatment of newly diagnosed patients with Multiple Myeloma with Bortezomib based regimens  »    PDF - 879 kB

Pieter Sonneveld, M.D.
Erasmus MC
Department of Hematology
Rotterdam, The Netherlands
Management of Bone Disease and Renal Impairment in Patients with Multiple Myeloma  »    PDF - 1.081 kB

Evangelos Terpos, M.D.
Department of Clinical Therapeutics
University of Athens School of Medicine
Athens, Greece


Waldenstrom’s Macroglobulinemia: Advances in the Biology and Therapy  »    PDF - 2.489 kB

Steven P. Treon, MD, MA, PhD
Director, Bing Center for Waldenstrom’s Macroglobulinemia
Dana Farber Cancer Institute
Harvard Medical School, USA




Elaborado por: Doctor en Medicina Artur Jurczyszyn

Cracovia, ‏15 de Septiembre 2009



Cuenta corriente en PLN  :  06 1440 1127 0000 0000 0835 9709